辉瑞中国独立医学教育项目请求书

In order to submit a request for Pfizer support of a China Independent Medical Education Grant, your request need to meet the following criteria:

• The activity aligns with Pfizer's Primary Areas of Interest (listed at the bottom)
• Geographic Scope/Location of Project is China
• The requested grant amount should not exceed $50,000

• Please go to https://www.cybergrants.com/pfizer/IndependentMedEd and sign in. First-time users should click “Create your password”.
• Click the " Start a New Independent Medical Education Application" button.

• Only organizations are eligible to receive grants, not individuals or medical practice groups.
• The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
• For projects offering continuing education credit, the requesting organization must be accredited.

Infectious Diseases

       Bacterial and fungal Diseases - Multidrug Resistant Gram-Negative Bacteria and Invasive fungal disease (IFD)

        For infectious disease (ID) physicians and all healthcare professionals involved in the care and treatment of patients suffering from infectious due to multidrug resistant Gram-Negative bacteria (MDR GNB) or IFD to increase the awareness and understand of topics including:

• PK/PD data and new methodologies like model-informed precision dosing (MIPD) to guide treatment selection and dosing of patients including special population (e.g. pediatric,elderly, ICU, septic shock, patients on ECMO and renal failure patients, including but not limited to those receiving CRRT)
• Use of rapid diagnostic tools, combination tests, images or other techniques for improvement of high-risk patient early identification, clinical diagnosis, appropriate management and early treatment of infections due to MDR GNB or IFD (focusing on moulds)
• Importance of epidemiology and surveillance to guide the appropriate use of antibiotics(AB/AF) to treat infections due to MDR GNB or IFD
• Evidence based practice including but not limited to Real World Evidence and its role in informed clinical practice-focus on MDR GNB or IFD, including CNS infection, and including Antimicrobial Stewardship and multidisciplinary team (MDT) framework

Autoimmune Diseases 

       Dermatology- Alopecia Areata

        For dermatologists and all healthcare professionals involved in the care and treatment of patients suffering from alopecia areata, increase the awareness and understanding of assessing disease severity, burden of disease, and the use of kinase inhibitors for the treatment of alopecia areata, including for adolescent patients.

       Dermatology- Atopic Dermatitis

        Improve the care of patients manifesting atopic dermatitis (AD) by increasing healthcare provider knowledge of the disease state or unmet need and the emerging strategies for treatment of AD.

       Dermatology- Vitiligo

        For dermatologists and all healthcare professionals involved in the care and treatment of patients with Vitiligo, increase the awareness and understanding of disease state, unmet needs, disease burden and assessing disease severity.

Cardiovascular Metabolic Risk

       Pain- Migraine

        To improve the care, management, and outcomes of adult patients with migraine by supporting HCP and patient education on topics including:

• Unmet need and disease burden associated with migraine
• The role of CGRP in the pathophysiology of migraine, as well as safety and efficiency of CGRP treatment
• CGRP receptor antagonists in the acute treatment of migraine and preventive treatment of episodic migraine
• The diagnosis and management of migraine by GPs and specialists (focus on acute treatment and prevention of episodic migraine)

Oncology

       Oncology – Breast

        For oncologists and all healthcare professionals involved in the care and treatment of patients with HR-positive breast cancer, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and real-world evidence studies, the clinical management of patients with HR-positive. Other topics of interest include sequencing strategies, optimizing clinical practice, application of real-world evidence to clinical decision-making, provider-patient shared decision-making, and implementation of clinical pathways.

       Oncology – Genitourinary – Prostate

        Increase understanding of PARP-inhibitor-class in prostate cancer including mechanisms of action in combination with NHTs, and genetic/biomarker-testing implications for clinical practice.

        Increase understanding of:

• differentiated mechanism of action (MOA) of emerging therapies including EZH2 inhibition and its possible role in prostate cancer
• EZH2 and other novel mechanisms of disease (MOD) and their role in prostate cancer progression
• the investigational thesis of how concomitant EZH2 and AR inhibition may suppress prostate cancer while delaying or overcoming ARPi resistance
• the continued unmet need for novel therapies in mCRPC

       Oncology – Genitourinary – Renal Cell Carcinoma (RCC)

        For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to patient care, especially with respect to treatment selection, sequencing, scheduling, dosing, adjuvant use, use of combination therapies, and management of side effects.

       Oncology – Hematologic

        Increase understanding in the following area:

          Multiple Myeloma

           Increase healthcare professional understanding of BCMAxCD3 bi-specifics therapies in relapsed/refractory multiple myeloma, including:

• Mechanisms of action
• Available clinical data – efficacy insights and side effect profiles
• Scientific rationale for potential sequencing of therapies
• Use of predictive or prognostic biomarkers
• Role of sBCMA on this therapeutic class
• Therapy management

       Oncology – Lung Cancer

        Increase the awareness and understanding of the importance of treating and managing patients with ALK mutated advanced NSCLC, including:

• Educating on the latest clinical updates, including efficacy and adverse event profiles
• Therapy management of ALK targeted therapies
• Address educational gaps in community oncology in diagnosis, treatment and management of ALK advanced NSCLC
• Provide education directly to patients on the importance of biomarker testing, active shared decision making, and AE management and support throughout the lung cancer treatment journey
• The role of the multi-disciplinary team collaboration and coordination of care in the treatment and management during ALK therapy

Rare Diseases

       Hemophilia

        Improve the care of patients by:

• Educating on the evolving treatment landscape (i.e. genetic medicine, rebalancing strategies) for hemophilia to improve the understanding of these novel approaches and their potential clinical applicability.
• Discussing shared decision making (SDM) and practical approaches on how SDM can be incorporated into hemophilia patient care
• Sharing knowledge and best practices (i.e. staff training, SOP, follow-up care) on how Hemophilia Treatment Centers (HTCs) and multidisciplinary team are preparing for novel therapies in development
• Advancing patient education on the evolving hemophilia treatment landscape and improving patient’s empowerment and ability to make informed decisions about their care

This category supports education of healthcare professionals and care teams that seeks to enlighten and inform so that health equity becomes part of practice, process, action, innovation, and/or organizational performance and outcomes.